Expression of pp60c-src in human small cell and non-small cell lung carcinomas - PubMed (original) (raw)
Expression of pp60c-src in human small cell and non-small cell lung carcinomas
N N Mazurenko et al. Eur J Cancer. 1992.
Abstract
c-src protein was found in 60% of lung carcinomas (20 of 33 cases or primary tumours) by immunoblotting with a monoclonal antibody (Mab 327) and immunohistochemistry with serum from rabbits bearing tumours induced by Rous sarcoma virus. src protein expression was assessed in 4 small cell lung carcinomas and in an atypical carcinoid of neuroendocrine origin. However, pp60c-src was also found in non-small cell lung carcinomas: in 60-80% of adenocarcinomas and bronchiolo-alveolar cancers and in 50% of squamous cell carcinomas. In the squamous cell carcinomas, src protein was expressed more frequently in poorly differentiated than in well and moderately differentiated carcinomas. Expression of pp60c-src was not found in epithelial cells of histologically unchanged lung tissues. These results show that pp60c-src may be activated in human lung carcinomas of different histopathological types.
Similar articles
- [The detection of the c-src protein gene product in human lung tumors].
Mazurenko NN, Kogan EA, Zborovskaia IB, Sukhova NM, Kiselev FL. Mazurenko NN, et al. Vopr Onkol. 1991;37(6):683-90. Vopr Onkol. 1991. PMID: 1726861 Russian. - Expression of ras p21 and myc p62 oncoproteins in small cell and non small cell carcinoma of the lung.
Spandidos DA, Zakinthinos S, Petraki C, Sotsiou F, Yiagnisis M, Dimopoulos AM, Roussos C, Field JK. Spandidos DA, et al. Anticancer Res. 1990 Sep-Oct;10(5A):1105-14. Anticancer Res. 1990. PMID: 2173469 - pp60c-src activation in lung adenocarcinoma.
Masaki T, Igarashi K, Tokuda M, Yukimasa S, Han F, Jin YJ, Li JQ, Yoneyama H, Uchida N, Fujita J, Yoshiji H, Watanabe S, Kurokohchi K, Kuriyama S. Masaki T, et al. Eur J Cancer. 2003 Jul;39(10):1447-55. doi: 10.1016/s0959-8049(03)00276-4. Eur J Cancer. 2003. PMID: 12826049 - src expression in small-cell lung carcinoma and other neuroendocrine malignancies.
Påhlman S, Hammerling U. Påhlman S, et al. Am Rev Respir Dis. 1990 Dec;142(6 Pt 2):S54-6. doi: 10.1164/ajrccm/142.6_Pt_2.S54. Am Rev Respir Dis. 1990. PMID: 2174663 Review. - Pathology of non-small cell lung cancer. New diagnostic approaches.
Linnoila I. Linnoila I. Hematol Oncol Clin North Am. 1990 Dec;4(6):1027-51. Hematol Oncol Clin North Am. 1990. PMID: 1962774 Review.
Cited by
- Activated PyK2 and Its Associated Molecules Transduce Cellular Signaling from the Cancerous Milieu for Cancer Metastasis.
Lee D, Hong JH. Lee D, et al. Int J Mol Sci. 2022 Dec 7;23(24):15475. doi: 10.3390/ijms232415475. Int J Mol Sci. 2022. PMID: 36555115 Free PMC article. Review. - A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).
Miller AA, Pang H, Hodgson L, Ramnath N, Otterson GA, Kelley MJ, Kratzke RA, Vokes EE; Cancer and Leukemia Group B (CALGB). Miller AA, et al. J Thorac Oncol. 2010 Mar;5(3):380-4. doi: 10.1097/JTO.0b013e3181cee36e. J Thorac Oncol. 2010. PMID: 20087228 Free PMC article. Clinical Trial. - A Phase I Study of the Non-Receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors.
Karim NA, Ullah A, Wang H, Shoukier M, Pulliam S, Khaled A, Patel N, Morris JC. Karim NA, et al. Curr Oncol. 2022 Dec 3;29(12):9461-9473. doi: 10.3390/curroncol29120744. Curr Oncol. 2022. PMID: 36547158 Free PMC article. Clinical Trial. - Predictive Biomarkers of Response to Src Inhibitors in Lung Cancer. Getting to YES1.
Li HY, Carr LL. Li HY, et al. Am J Respir Crit Care Med. 2019 Oct 1;200(7):802-804. doi: 10.1164/rccm.201905-1092ED. Am J Respir Crit Care Med. 2019. PMID: 31206303 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous